Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock. Several other equities analysts have also recently issued reports on the company. Benchmark reduced their price objective on Humacyte from $17.00 […]

Jun 10, 2025 - 07:16

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock. Several other equities analysts have also recently issued reports on the company. Benchmark reduced their price objective on Humacyte from $17.00 […]